Tower Research Capital (TRC)’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-700
| Closed | -$91 | – | 5115 |
|
|
2025
Q3 | $91 | Sell |
700
-10,221
| -94% | -$1.4K | ﹤0.01% | 5115 |
|
|
2025
Q2 | $2.62K | Sell |
10,921
-11,045
| -50% | -$2.95K | ﹤0.01% | 4622 |
|
|
2025
Q1 | $4.33K | Buy |
21,966
+2,436
| +12% | +$1.26K | ﹤0.01% | 4275 |
|
|
2024
Q4 | $10.5K | Buy |
19,530
+14,865
| +319% | +$10.8K | ﹤0.01% | 3795 |
|
|
2024
Q3 | $4.43K | Buy |
+4,665
| New | +$5.29K | ﹤0.01% | 4545 |
|
|
2024
Q1 | – | Sell |
-10,664
| Closed | -$8.46K | – | 5829 |
|
|
2023
Q4 | $8.46K | Buy |
10,664
+2,627
| +33% | +$1.48K | ﹤0.01% | 4509 |
|
|
2023
Q3 | $6.27K | Sell |
8,037
-8,037
| -50% | -$6.75K | ﹤0.01% | 4626 |
|
|
2023
Q2 | $14.9K | Buy |
16,074
+3,802
| +31% | +$4.53K | ﹤0.01% | 3665 |
|
|
2023
Q1 | $13K | Buy |
12,272
+4,284
| +54% | +$6.64K | ﹤0.01% | 3944 |
|
|
2022
Q4 | $12K | Sell |
7,988
-21,882
| -73% | -$35.4K | ﹤0.01% | 3668 |
|
|
2022
Q3 | $32K | Buy |
29,870
+486
| +2% | +$893 | ﹤0.01% | 3534 |
|
|
2022
Q2 | $50K | Buy |
29,384
+24,671
| +523% | +$42.4K | ﹤0.01% | 2869 |
|
|
2022
Q1 | $10K | Sell |
4,713
-1,215
| -20% | -$3.28K | ﹤0.01% | 4267 |
|
|
2021
Q4 | $22K | Sell |
5,928
-3,151
| -35% | -$14.3K | ﹤0.01% | 3543 |
|
|
2021
Q3 | $47K | Buy |
9,079
+4,839
| +114% | +$21.7K | ﹤0.01% | 3008 |
|
|
2021
Q2 | $18K | Sell |
4,240
-1,435
| -25% | -$6.96K | ﹤0.01% | 3976 |
|
|
2021
Q1 | $30K | Buy |
5,675
+2,992
| +112% | +$17.1K | ﹤0.01% | 3556 |
|
|
2020
Q4 | $14K | Buy |
+2,683
| New | +$14.6K | ﹤0.01% | 4080 |
|
|
2020
Q2 | – | Sell |
-9,591
| Closed | -$26K | – | 4716 |
|
|
2020
Q1 | $26K | Buy |
9,591
+9,429
| +5,820% | +$31.3K | ﹤0.01% | 1586 |
|
|
2019
Q4 | $0 | Sell |
162
-21,310
| -99% | -$22.7K | ﹤0.01% | 3447 |
|
|
2019
Q3 | $32K | Buy |
21,472
+21,372
| +21,372% | +$50K | ﹤0.01% | 2127 |
|
|
2019
Q2 | $0 | Sell |
100
-6,290
| -98% | -$25.6K | ﹤0.01% | 3593 |
|
|
2019
Q1 | $27K | Buy |
+6,390
| New | +$29.8K | ﹤0.01% | 2100 |
|
|
2018
Q4 | – | Sell |
-496
| Closed | -$7K | – | 3777 |
|
|
2018
Q3 | $7K | Sell |
496
-1,465
| -75% | -$15.4K | ﹤0.01% | 2940 |
|
|
2018
Q2 | $23K | Sell |
1,961
-1,360
| -41% | -$17K | ﹤0.01% | 2342 |
|
|
2018
Q1 | $37K | Sell |
3,321
-1,501
| -31% | -$13.1K | ﹤0.01% | 1840 |
|
|
2017
Q4 | $32K | Buy |
+4,822
| New | +$37.2K | ﹤0.01% | 1677 |
|
|
2017
Q3 | – | Sell |
-3,663
| Closed | -$16K | – | 3740 |
|
|
2017
Q2 | $16K | Buy |
+3,663
| New | +$19.1K | ﹤0.01% | 1331 |
|
|
2017
Q1 | – | Sell |
-288
| Closed | -$1K | – | 2982 |
|
|
2016
Q4 | $1K | Sell |
288
-1,249
| -81% | -$5.99K | ﹤0.01% | 3555 |
|
|
2016
Q3 | $11K | Buy |
1,537
+1,329
| +639% | +$10.1K | ﹤0.01% | 1988 |
|
|
2016
Q2 | $2K | Buy |
+208
| New | +$1.96K | ﹤0.01% | 3851 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
Tower Research Capital (TRC)'s ADAP Position: Q4 2025 in Review
Tower Research Capital (TRC) sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 700 shares — an estimated $91 sold.
Tower Research Capital (TRC) first reported a position in ADAP in Q2 2016 and held it in 31 quarters. The position peaked at $50K in Q2 2022. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.
- Tower Research Capital (TRC) reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 700 Adaptimmune Therapeutics shares in Q4 2025, an estimated $91.
- Tower Research Capital (TRC) first reported a position in Adaptimmune Therapeutics in Q2 2016 and held it in 31 quarters.
- Tower Research Capital (TRC)'s Adaptimmune Therapeutics position peaked at $50K in Q2 2022.
- 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.